Strategic alliance focuses on scaling data-integrated sleep solutions to meet surging clinical and consumer demand

SAN FRANCISCO–(BUSINESS WIRE)–ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy^® and pioneer in Smart Sleep Medicine™, today announced a strategic investment from Catalio Capital Management, L.P. to accelerate the global expansion of its technology-enabled sleep health platform.

Under the agreement, Catalio, a premier healthcare-focused investment firm, has committed up to $38 million to advance development of next-generation remote patient monitoring (RPM) and proprietary sleep diagnostic devices, fund comparative clinical studies, and scale the infrastructure needed to meet surging demand for patient-preferred OSA therapies.

Len Liptak, CEO of ProSomnus, said: “Catalio’s investment affirms our mission to address the global public health burden of obstructive sleep apnea with precision, data‑driven medical solutions that create meaningful value loops for patients, clinicians, and payers. Demand for effective, economical, and patient‑preferred therapies continues to build. This partnership enables ProSomnus to expand access to care while advancing and scientifically validating our next generation sensor‑enabled medical devices. We appreciate Catalio’s partnership and look forward to accelerating the worldwide adoption of Smart Sleep Medicine.”

Jason Orchard, CFO of ProSomnus, added: “This $38 million commitment provides the strategic financial framework to scale our core infrastructure while maintaining a relentless focus on the patient. By directing capital into advanced remote monitoring and rigorous clinical validation, we are ensuring our growth is measured not just by market share, but by demonstrable patient outcomes. These investments allow us to lower the cost of care, increase treatment efficacy, and create a sustainable model for both our shareholders and the patients we serve.”

Catalio’s Dr. Nicholas von Guionneau has joined the ProSomnus Board as an Observer. He commented: “Sleep medicine is rapidly shifting toward data-driven, patient-preferred therapies. ProSomnus is leading that transition with connected oral devices that are clinically effective and consistently used by patients. We’re excited to strategically support the global launch of their next-generation product and broader vision for a scalable connected sleep medicine platform.”

About ProSomnus Sleep Technologies Inc.

ProSomnus is the pioneer and global leader in Smart Sleep Medicine, providing a technology-enabled, non-CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA). A serious medical disease affecting over 1 billion people worldwide, OSA is linked to life-threatening comorbidities including heart failure, stroke, and type 2 diabetes.

By integrating precision-engineered intraoral medical devices with advanced remote patient monitoring (RPM) and data-driven diagnostics, ProSomnus is redefining the standard of care. Our platform is designed to provide continuous, nightly clinical insights that ensure superior adherence and validated patient outcomes. Non-invasive and patient-preferred, ProSomnus devices have demonstrated exceptional efficacy and safety across a rigorous and growing body of clinical evidence. ProSomnus precision devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, and TRICARE, representing over 200 million covered lives globally. To learn more about the future of sleep health, visit www.ProSomnus.com.

About Catalio Capital Management, LP:

Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting www.cataliocapital.com.

Contacts

Media Contacts
For ProSomnus:
Heather Whalen
hwhalen@prosomnus.com

For Catalio Capital Management:
catalio@rubenstein.com

(c)2026 Business Wire, Inc., All rights reserved.